pre-update Archives

Press Release

Certara Reports Third Quarter 2024 Financial Results

Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024-- Certara, Inc. (Nasdaq: CERT),…

CertaraNovember 6, 2024

Press Coverage

How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product

Establishing bioequivalence for topical drug products can be challenging and costly, often requiring extensive comparative…

CertaraNovember 5, 2024

On-Demand Webinar

Partnership for Pioneering Pharmaceutical Advancement; Development of Rimegepant for Migraine Therapy

CertaraNovember 5, 2024

Publication

Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody

The article titled "Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a…

CertaraNovember 4, 2024

On-Demand Webinar

Improved Translation of Clinical TCE Dosing with Mechanistic Modeling

Abstract: Regulatory agencies recommend quantitative justifications for clinical dose selection. T-cell engagers (TCE) pose particular…

CertaraOctober 31, 2024

On-Demand Webinar

Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1

Abstract: Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked…

CertaraOctober 31, 2024

On-Demand Webinar

Guiding Target and Lead Optimization for a Molecular Glue Degrader

Learn how to optimize drug properties for protein degrader therapeutics by exploring system characteristics.

CertaraOctober 31, 2024

On-Demand Webinar

Capturing CAR T-cell Therapy Dynamics Through Mechanistic Modeling

Abstract: Chimeric antigen receptor T (CAR T)-cell therapy has shown remarkable success in treating various…

CertaraOctober 31, 2024

Video

Part 5: Regulatory Outlook on Data Management

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara…

CertaraOctober 31, 2024

Video

Part 4: Consequences of Improper Data Collection

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara…

CertaraOctober 31, 2024

pre-update

Certara Reports Third Quarter 2024 Financial Results

How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product

Partnership for Pioneering Pharmaceutical Advancement; Development of Rimegepant for Migraine Therapy

Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody

Improved Translation of Clinical TCE Dosing with Mechanistic Modeling

Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1

Guiding Target and Lead Optimization for a Molecular Glue Degrader

Capturing CAR T-cell Therapy Dynamics Through Mechanistic Modeling

Part 5: Regulatory Outlook on Data Management

Part 4: Consequences of Improper Data Collection

Newsletter sign up

Quick links

Solutions

Contact